Female Gender and Carcinoma In Situ in the Prostatic Urethra Are Prognostic Factors for Recurrence, Progression, and Disease-Specific Mortality in T1G3 Bladder Cancer Patients Treated With Bacillus Calmette-Guérin-Reference-Cited by-同舟云学术

Female Gender and Carcinoma In Situ in the Prostatic Urethra Are Prognostic Factors for Recurrence, Progression, and Disease-Specific Mortality in T1G3 Bladder Cancer Patients Treated With Bacillus Calmette-Guérin

Published:2012-07 Issue:1 Volume:62 Page:118-125
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Palou Joan,Sylvester Richard J.,Faba Oscar Rodríguez,Parada Rubén,Peña Juan A.,Algaba Ferran,Villavicencio Humberto

Publisher

Elsevier BV

Subject

Urology

Reference28 articles.

1. EAU guidelines on non–muscle-invasive urothelial carcinoma of the bladder, the 2011 update;Babjuk;Eur Urol,2011

2. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence;Millán-Rodríguez;J Urol,2000

3. Club Urológico Español De Tratamiento Oncológico (CUETO). Prognostic factors in patients with non–muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials;Fernández-Gomez;Eur Urol,2008

4. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients;Orsola;Eur Urol,2005

5. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study;Lamm;J Urol,2000

Cited by 204 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incidence and management of prostatic urethra recurrence in a cohort of 21 patients who received BCG induction for non-muscle invasive bladder cancer;Urologic Oncology: Seminars and Original Investigations;2024-09

2. Evaluating the Quality of Primary Transurethral Resection of Bladder Tumor: A Nine-Year Review at a Tertiary Healthcare Center;Cureus;2024-08-29

3. European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)—A Summary of the 2024 Guidelines Update;European Urology;2024-08

4. Optimal timing for the first cystoscopic follow-up using time-to-treatment initiation analysis of oncologic outcomes in primary non-muscle invasive bladder cancer;Scientific Reports;2024-04-10

5. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment;Journal of Urology;2024-04